FLT3 and acute myeloid leukemia: In summary, the present meta‐analysis demonstrates that FLT3i maintenance therapy following allo‐HSCT, mainly midostaurin and sorafenib, can reduce relapse risk and prolong survival in FLT3‐mutated AML patients, and that the inhibitors are well tolerated.